3 results
The primary objective of this study is to compare overall survival (OS) in patients receiving Marizomib in combination with standard treatment (TMZ with concomitant RT, followed by TMZ maintenance therapy: TMZ/RT*TMZ) with patients receiving…
In this study we will investigate how safe the new compound leniolisib is and how well it is tolerated by healthy male participants.We also investigate how quickly and to what extent leniolisib is absorbed, transported, and eliminated from the body…
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…